 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Labatec-Pharma S.A. |
| Street 1: | 31, Rue du Cardinal-Journet |
| Street 2: | |
| City: | Geneve |
| Province: | |
| Post Code: | 1217 |
| Country: | Switzerland |
| Phone: | 0041227859500 |
| Organization Email: | info@labatec.ch |
| Web Site: | http://www.labatecpharma.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | Private sector |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | None |
| Organization Description: | |
| Labatec Pharma is a Swiss pharmaceuticals company based in Geneva backed by more than 50 years’ experience in proposing high-quality products. Labatec The contribution of Labatec Labatec: a reliable partner for treating Tuberculosis With a strong portfolio of current and underdevelopment anti-tuberculosis drugs, we are committed to supply critical medication for this disease worldwide. Currently Myambutol 100mg and 400mg (Ethambutol), Rifampicine 150mg and 300mg, are under assessment by the World Health Organisation for Prequalification. Most of our products are listed on the Global Fund Anti TB list of Pharmaceutical Suppliers. Labatec provides Swiss Hospitals and Patients with: •Isoniazid 100 mg & 300 mg Labatec has a renewable import market authorisation from Swissmedic for Isoniazid 100mg (tablets). Isoniazid is registered and manufactured in the USA in FDA approved facilities. We currently have stock to cover the full needs of all Swiss hospitals and pharmacies. Starting in March 2012, Isoniazid has been integrated into the Reimbursement List of Specialties in Switzerland. •Ethambutol 100 and 400 mg •Rifampicine 150 and 300 mg •Pyrazinamide 500 mg The remaining three molecules are manufactured in our Geneva Switzerland facilities. |
|
| Do you know about the UNHLM declaration: | |
Specializations / Areas of Work | |
|
Provision of drugs, diagnostics and commodities |
Other Organization Information | |
| Total number of staff in your organization: | 26 - 50 |
| Number of full-time staff who are directly involved with TB: | 1 - 5 |
| Number of part-time staff who are directly involved with TB: | 0 |
| Number of volunteers who are directly involved with TB: | 0 |
| How did you hear about the Stop TB Partnership: | Involvement in TB control provision |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Labatec provides Swiss Hospitals and Patients with: •Isoniazid 100 mg & 300 mg |
|
Geographical Reach | |
| Which country is your headquarters located in: | Switzerland |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Afghanistan Albania Algeria Andorra Angola Antigua and Barbuda Argentina Armenia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Central African Republic Chad Chile China Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic People's Republic of Korea Democratic Republic of the Congo Democratic Republic of Timor-Leste Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Eswatini Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Greece Grenada Guatemala Guinea Guinea-Bissau Guyana Haiti Honduras Hungary Iceland India Indonesia Iran (Islamic Republic of) Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Lithuania Luxembourg Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Micronesia (Federated States of) Monaco Mongolia Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Zealand Nicaragua Niger Nigeria Niue Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Qatar Republic of Korea Republic of Moldova Republic of Montenegro Republic of Serbia Romania Russian Federation Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Sudan Spain Sri Lanka Sudan Suriname Sweden Switzerland Syrian Arab Republic Tajikistan Thailand The Former Yugoslav Rep of Macedonia Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Tuvalu Uganda Ukraine United Arab Emirates United Kingdom of Great Britain and Northern Ireland United Republic of Tanzania United States of America Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Yemen Zambia Zimbabwe |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB Care Delivery: work with MOH increasingly to educate on drug quality, high standard Drug-Resistant TB: development of MDR-TB drugs New TB Drugs: Develeopment of drug innovations |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | August 24, 2012 |
| Last updated: | May 14, 2018 |